The offer hopes to resolve competition concerns over the supply of a fludrocortisone acetate 0.1 mg tablets.
News
Lynparza hits target in late stage ovarian cancer trial
he companies announced earlier this month that the drug was also successful in prostate cancer.
RCGP highlights dangers of antibiotics for children when not ‘absolutely necessary’
30% of antibiotics prescribed in outpatient settings in the US, and between 9% and 23% in UK primary care are unnecessary.
Novel chlamydia vaccine proves safe in early trial
The positive safety results show that the experimental treatment could become a promising early candidate for a chlamydia vaccine.
NHS strengthens Long Term Plan with digital diabetes prevention roll-out
Almost seven in 10 people referred to digital schemes took part compared with around half of those offered face-to-face support.
SMC rejects Orkambi, accepts four medicines
The rejection was due to ‘uncertainties in the company’s evidence about the long term health benefits of both medicines in relation to their costs.’
Asthma deaths ‘highest this decade’
Professor Helen Stokes-Lampard, chair of the Royal College of GPs said the figures are “deeply concerning”.
Average GP waiting times now ‘exceed two weeks’
Data from a new report show that the waiting times now exceed a fortnight, for the first time ever.
Tremfya tops Cosentyx in late-stage study
The study is the first to compare Tremfya and the IL-17 inhibitor, Cosentyx.
LIVI announces new NHS partnerships
Video consultations have been cited as a way to take the strain off GPs.
NICE highlights need for more cannabis-based research
NHS England has also published a review aimed at assessing the barriers to prescribing cannabis-based medicinal products.
Latest performance stats show NHS is ‘struggling’
The number of A&E patients in England waiting on trolleys for more than four hours is the highest since records began.
Ipsen launches new self-injection Somatuline option
Good news for adult patients with gastroenteropancreatic neuroendocrine tumours.
Bayer acquires BlueRock in cell therapy move
After the acquisition, Bayer will own full rights to BlueRock Therapeutics’ CELL+GENE platform.
NHS publishes list of suppliers to boost purchasers’ confidence
The organisations have developed a new section on the Health Systems Support Framework.
